777 Old Saw Mill River Rd, Tarrytown, New York, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: https://www.regeneron.com/
According to the market data, Regeneron Pharmaceuticals, Inc. (REGN) stock price is $490.43 and the 52 weeks low is $441, which means the Regeneron Pharmaceuticals, Inc. stock price is down -9.25% in the last 12 months.
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price is not Trending currently as per the Weekly Chart, which means the price may range between specific high and low levels for the next few months, unless some significant changes take place in the market performance or news.
Technical Indicators are algorithms that are used mostly by Technical traders to predict the price action of a stock.
Based on our analysis of 16 technical indicators, 6.25% are indicating that REGN Stock price might rise further, 43.75% indicating that REGN Stock price might fall, and 50.00% are in a neutral position.
Based on these technical algorithms, overall REGN stock price has a Neutral Signal, which means the stock price has the potential to move either up or down, depending on the nature of consolidating market phase, since majority of indicators are providing a neutral signal.
Out of 32 Institutional Analysts, majority recommended REGN stock as Strong Buy. Since most investors and traders follow analyst ratings closely, this can be a potentially driving factor for the future stock price of Regeneron Pharmaceuticals, Inc..
High | Low | Average |
---|---|---|
$833.70 | $481.77 | $656.23 |
The average price target for REGN by Institutional Analysts is $656.23, which is 33.81% Upside from the current price. So according to the Institutional Analysts, REGN Stock might be a bit undervalued at this stage and there’s potential for upside.
However, although Institutional Analysts set their price targets after extensive research, they’re not always correct. After all, the market is mostly driven by investors speculation and emotion than just concrete numbers.
According to the news articles published last week, most journalists and bloggers talked positively about REGN, it shows that Regeneron Pharmaceuticals, Inc. had a 100.00% positive news coverage.
Positive news coverage usually affects short-term price of a stock, so this positive coverage provides an indication that REGN stock price may surge in the next few weeks.
Analyst | Recommendation | Action |
---|---|---|
Morgan Stanley | Equal-Weight | Maintained |
SVB Leerink | Outperform | Maintained |
Credit Suisse | Outperform | Maintained |
Cantor Fitzgerald | Overweight | Maintained |
SVB Leerink | Outperform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Credit Suisse | Outperform | Maintained |
Cowen & Co. | Outperform | Maintained |
BMO Capital | Outperform | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
Citigroup | Buy | Maintained |
Benchmark | Buy | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
Credit Suisse | Outperform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
SVB Leerink | Outperform | Maintained |
Credit Suisse | Outperform | Maintained |
BMO Capital | Market Perform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
SVB Leerink | Outperform | Maintained |
Cantor Fitzgerald | Overweight | Upgraded |
Benchmark | Hold | Downgraded |
Credit Suisse | Outperform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Citigroup | Neutral | Maintained |
BMO Capital | Market Perform | Maintained |
Credit Suisse | Outperform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
SunTrust Robinson Humphrey | Buy | Upgraded |
Canaccord Genuity | Buy | Maintained |
Oppenheimer | Outperform | Maintained |
Credit Suisse | Outperform | Maintained |
Jefferies | Buy | Maintained |
SVB Leerink | Outperform | Reiterated |
CFRA | Hold | Maintained |
Wells Fargo | Overweight | Upgraded |
SVB Leerink | Outperform | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Credit Suisse | Outperform | Maintained |
BMO Capital | Market Perform | Maintained |
Baird | Neutral | Maintained |
Citigroup | Neutral | Downgraded |
Canaccord Genuity | Buy | Maintained |
Benchmark | Buy | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
JP Morgan | Neutral | Maintained |
Benchmark | Hold | Initiated |
SVB Leerink | Outperform | Maintained |
Wells Fargo | Equal-Weight | Maintained |
Argus Research | Buy | Maintained |
Oppenheimer | Outperform | Maintained |
CFRA | Hold | Downgraded |
Credit Suisse | Outperform | Maintained |
Canaccord Genuity | Buy | Upgraded |
Baird | Neutral | Downgraded |
Jefferies | Buy | Upgraded |
Evercore ISI Group | Outperform | Upgraded |
Argus Research | Buy | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Raymond James | Market Perform | Initiated |
Evercore ISI Group | In-Line | Downgraded |
Credit Suisse | Outperform | Upgraded |
SunTrust Robinson Humphrey | Hold | Initiated |
Citigroup | Buy | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
Credit Suisse | Neutral | Maintained |
BMO Capital | Market Perform | Maintained |
Canaccord Genuity | Hold | Maintained |
Guggenheim | Buy | Upgraded |
Baird | Outperform | Upgraded |
Argus | Hold | Downgraded |
Citigroup | Neutral | Maintained |
Credit Suisse | Neutral | Initiated |
Cantor Fitzgerald | Neutral | Maintained |
UBS | Buy | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
BMO Capital | Market Perform | Maintained |
Guggenheim | Neutral | Downgraded |
Guggenheim | Buy | Upgraded |
Goldman Sachs | Buy | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
Canaccord Genuity | Hold | Maintained |
Cantor Fitzgerald | Neutral | Initiated |
Barclays | Underweight | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Canaccord Genuity | Hold | Maintained |
Baird | Neutral | Downgraded |
Argus | Buy | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
Oppenheimer | Outperform | Upgraded |
Morgan Stanley | Equal-Weight | Maintained |
BMO Capital | Market Perform | Maintained |
Guggenheim | Neutral | Downgraded |
Raymond James | Market Perform | Downgraded |
Canaccord Genuity | Hold | Downgraded |
Morgan Stanley | Equal-Weight | Maintained |
Leerink Swann | Outperform | Maintained |
BTIG Research | Neutral | Downgraded |
BMO Capital | Market Perform | Maintained |
Baird | Outperform | Upgraded |
JP Morgan | Neutral | Maintained |
Deutsche Bank | Hold | Initiated |
Citigroup | Neutral | Downgraded |
BTIG Research | Buy | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
BMO Capital | Market Perform | Maintained |
Baird | Neutral | Upgraded |
Barclays | Underweight | Downgraded |
Morgan Stanley | Equal-Weight | Maintained |
UBS | Buy | Maintained |
RBC Capital | Sector Perform | Initiated |
Evercore ISI Group | Outperform | Initiated |
Baird | Underperform | Downgraded |
Morgan Stanley | Equal-Weight | Maintained |
Bernstein | Market Perform | Downgraded |
Canaccord Genuity | Buy | Upgraded |
UBS | Buy | Initiated |
PiperJaffray | Overweight | Upgraded |
BMO Capital | Market Perform | Initiated |
BTIG Research | Buy | Upgraded |
Chardan Capital | Neutral | Upgraded |
Baird | Neutral | Downgraded |
Bernstein | Outperform | Initiated |
Wells Fargo | Market Perform | Downgraded |
Roth Capital | Buy | Maintained |
Leerink Swann | Outperform | Maintained |
Chardan Capital | Sell | Downgraded |
Gabelli & Co. | Buy | Initiated |
SunTrust Robinson Humphrey | Neutral | Initiated |
Citigroup | Buy | Initiated |
Chardan Capital | Neutral | Upgraded |
UBS | Buy | Maintained |
Morgan Stanley | Equal-Weight | Maintained |
JP Morgan | Neutral | Maintained |
Brean Capital | Buy | Maintained |
Barclays | Equal-Weight | Maintained |
Leerink Swann | Outperform | Initiated |
Canaccord Genuity | Hold | Downgraded |
Chardan Capital | Sell | Downgraded |
Credit Suisse | Neutral | Initiated |
Roth Capital | Buy | Upgraded |
BTIG Research | Neutral | Initiated |
Wells Fargo | Outperform | Initiated |
Morgan Stanley | Equal-Weight | Downgraded |
UBS | Buy | Upgraded |
Chardan Capital | Neutral | Downgraded |
Barclays | Equal-Weight | Maintained |
Morgan Stanley | Overweight | Maintained |
Brean Capital | Buy | Maintained |
Jefferies | Hold | Maintained |
RBC Capital | Outperform | Maintained |
Deutsche Bank | Buy | Maintained |
UBS | Sell | Downgraded |
RBC Capital | Outperform | Maintained |
Baird | Outperform | Maintained |
Citigroup | Buy | Maintained |
Leerink Swann | Outperform | Maintained |
Chardan Capital | Buy | Initiated |
Bernstein | Outperform | Initiated |
PiperJaffray | Neutral | Downgraded |
Citigroup | Buy | Maintained |
Barclays | Equal-weight | Initiated |
Morgan Stanley | Overweight | Upgraded |
Bank of America | Buy | Maintained |
Brean Capital | Buy | Maintained |
Argus | Buy | Maintained |
Guggenheim | Buy | Initiated |
Credit Suisse | Outperform | Maintained |
Brean Capital | Buy | Maintained |
Deutsche Bank | Buy | Maintained |
Argus Capital | Buy | Initiated |
UBS | Neutral | Maintained |
Canaccord Genuity | Buy | Initiated |
Roth Capital | Buy | Maintained |
Morgan Stanley | Equal-Weight | Initiated |
Citigroup | Buy | Upgraded |
Oppenheimer | Market Perform | Downgraded |
Deutsche Bank | Buy | Maintained |
Citigroup | Neutral | Maintained |
BMO Capital | Market Perform | Downgraded |
PiperJaffray | Overweight | Initiated |
BMO Capital | Outperform | Maintained |
PiperJaffray | Overweight | Maintained |
Leerink Swann | Outperform | Maintained |
Deutsche Bank | Buy | Maintained |
Bank of America | Buy | Maintained |
PiperJaffray | Overweight | Maintained |
Oppenheimer | Outperform | Maintained |
Goldman Sachs | Buy | Maintained |
RBC Capital | Outperform | Maintained |
Lazard | Buy | Maintained |
Oppenheimer | Outperform | Initiated |
PiperJaffray | Overweight | Maintained |
Lazard | Buy | Upgraded |
PiperJaffray | Overweight | Upgraded |
Brean Capital | Buy | Upgraded |
Goldman Sachs | Buy | Maintained |
Bank of America | Buy | Maintained |
Goldman Sachs | Buy | Maintained |
JMP Securities | Market Perform | Initiated |
Barclays | Overweight | Initiated |
Brean Capital | Hold | Downgraded |
Jefferies | Hold | Downgraded |
Credit Suisse | Outperform | Initiated |
Deutsche Bank | Buy | Maintained |
Jefferies | Buy | Maintained |
Goldman Sachs | Buy | Maintained |
Deutsche Bank | Buy | Maintained |
Citigroup | Neutral | Maintained |
PiperJaffray | Neutral | Maintained |
Bank of America | Buy | Maintained |
Goldman Sachs | Buy | Maintained |
Bank of America | Buy | Maintained |
PiperJaffray | Neutral | Maintained |
BMO Capital | Outperform | Upgraded |
Bank oferica | Buy | Maintained |
Jefferies | Buy | Maintained |
Goldman Sachs | Buy | Maintained |
Bank oferica | Buy | Maintained |
Jefferies | Buy | Maintained |
PiperJaffray | Neutral | Maintained |
Brean Capital | Buy | Maintained |
Bank oferica | Buy | Maintained |
Bank oferica | Buy | Maintained |
Bank oferica | Buy | Maintained |
PiperJaffray | Neutral | Maintained |
Actual | Estimate | Date |
---|---|---|
$8.36 | $7.2780569999999996 | 2020-09-30 |
The latest average Earning Per Share Estimate for Regeneron Pharmaceuticals, Inc. is $14.64, which is higher than REGN's last EPS, $8.36. This means that Analysts are expecting Regeneron Pharmaceuticals, Inc. to report higher earnings. This can drive share prices higher since the investors have positive sentiment about market performance of Regeneron Pharmaceuticals, Inc..
Actual | Estimate | Date |
---|---|---|
$8.36 | $7.2780569999999996 | 2020-09-30 |
$7.16 | $6.102864 | 2020-06-30 |
$6.6 | $6.254385 | 2020-03-31 |
$7.5 | $7.0610826 | 2019-12-31 |
$6.67 | $6.4891890000000005 | 2019-09-30 |
$6.02 | $5.515201200000001 | 2019-06-30 |
$4.45 | $5.5829699999999995 | 2019-03-31 |
$6.84 | $5.7105006000000005 | 2018-12-31 |
$5.87 | $5.235711 | 2018-09-30 |
$5.45 | $4.790062799999999 | 2018-06-30 |
$4.67 | $4.4397846 | 2018-03-31 |
$5.23 | $4.6176216 | 2017-12-31 |
$3.99 | $3.9261126 | 2017-09-30 |
$4.17 | $3.2309214 | 2017-06-30 |
$2.92 | $3.1225158 | 2017-03-31 |
$3.04 | $3.0881010000000004 | 2016-12-31 |
$3.13 | $2.7608136 | 2016-09-30 |
$2.82 | $2.7023982 | 2016-06-30 |
$2.57 | $2.6327220000000002 | 2016-03-31 |
$2.83 | $3.4257516 | 2015-12-31 |
$3.47 | $3.25941 | 2015-09-30 |
$2.89 | $2.82693 | 2015-06-30 |
$2.88 | $2.7361500000000003 | 2015-03-31 |
$2.79 | $2.8721976 | 2014-12-31 |
$2.52 | $2.62548 | 2014-09-30 |
$2.47 | $2.3409 | 2014-06-30 |
$2.26 | $2.244 | 2014-03-31 |
$0.86 | $1.0021908 | 2013-12-31 |
$1.25 | $0.9224778 | 2013-09-30 |
$0.79 | $0.8947746 | 2013-06-30 |
$0.9 | $0.9976926 | 2013-03-31 |
$1.22 | $1.1213165999999999 | 2012-12-31 |
$1.72 | $0.9639 | 2012-09-30 |
$0.7 | $0.2717586 | 2012-06-30 |
$0.16 | $-0.2346 | 2012-03-31 |
$-0.54 | $-0.6127241999999999 | 2011-12-31 |
$-0.68 | $-0.7731600000000001 | 2011-09-30 |
$-0.69 | $-0.41649660000000005 | 2011-06-30 |
$-0.49 | $-0.36516 | 2011-03-31 |
$-0.17 | $-0.32844 | 2010-12-31 |
The analysts provide Buy, Sell or Hold ratings after extensive research of a companies financial reports, listening to conference calls and some of them even get in contact with upper management of the company to get an overall picture of operation.
Although institutional Analyst’s are not always correct, their ratings are followed by millions of traders around the world and they can heavily influence trading activities for a company.
As a retail investor, going through analyst ratings will instantly provide you an idea if the stock is worth buying. Top Analysts also provide their price targets. It’s a prediction of where the stock price might go based on their analysis.
The best way to analyze price targets is to combined average price targets of major analysts. If the average price target is much higher than the current price of the stock, then the probability of a stock going up is also high.
Technical Analysis refers to analyzing a stock's price over a period of time. In the financial market, past price patterns are one of the strongest indicators of an asset's future performance.
In easier terms, millions of traders use Live Charts to watch the stock prices, it is actually a single source of truth for most traders. When a stock's price reaches a significant price level/pattern in the chart, millions of traders take buy/sell positions from those levels.
As a regular investor, one of the easiest ways to check technical analysis of a stock is through Technical Indicators. Technical Indicators are programmed algorithms that monitor price changes in the Charts and indicate Buy/Sell based on market conditions.
Some Technical Indicators can be very powerful (e.g SMA) and some can be pretty useless. Stock research tools like iTradely heavily simplify the technical analysis process for the investors by showing Buy/Sell/Neutral ratings combined from 17 powerful technical indicators, all in one page.
EPS, or Earning Per Share, can tell a lot about a stock’s performance. It’s calculated by dividing a company’s profit by the number of outstanding shares of its common stocks.
In layman’s term, earnings is an indicator of a company’s profitability. Higher the earnings, the more profitable a company is.
Some traders pick stocks solely based on EPS or earnings Analysis, it is a very powerful indicator of a stock’s price.
Before you buy a stock, check the company’s earnings History and Surprises. A Surprise happens when a company reports a much higher or lower actual earnings/EPS than the forecasted earnings/EPS.
If a company reports higher EPS surprises consistently, analysts keep raising their estimates, traders become more confident in the company, driving the share price higher.
Stock Sentiment refers to how people speculating about the stock or what kind of trading position investors are often taking.
There are different kinds of sentiments you can find online for a company, this includes Investor Sentiment (Percentage of investors buying or selling), News Sentiment (Is the company getting positive or negative impressions from the Press?), Social Sentiment (The overall trends about the company in social media, is it negative or positive?).